RE: Avacta has a USP - Affimers!30 May 2020 07:49
Medusa19 has the exclusive distribution rights to directly deliver to consumers a saliva based rapid test, currently under development by Avacta Group Plc, for the COVID-19 antigen, subject to regulatory approval. As such, its immediate priority is to invest in the necessary functions that will enable Avacta’s test to be rapidly and globally deployed once it becomes available.